The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
Abstract
INTRODUCTION: Novel peroxisome proliferator-activated receptor (PPAR) modulators (selective PPAR modulators [SPPARMs]) and dual PPAR agonists may have an important role in the treatment of cardiometabolic disorders owing to lipid-modifying, insulin-sensitizing and anti-inflammatory effects. AREAS COVERED: This review summarizes the efficacy of new PPAR agonists and SPPARMs that are under development for the treatment of atherogenic dyslipidemia and non-alcoholic fatty liver disease (NAFLD). EXPERT OPINION: ABT-335 is a new formulation of fenofibrate that has been approved for concomitant use with statins. K-877, a SPPARM-α with encouraging preliminary results in modulating atherogenic dyslipidemia, and INT131, a SPPARM-γ with predominantly insulin-sensitizing actions, may also have favorable lipid-modifying effects. Although the development of dual PPAR-α/γ agonists (glitazars) and the SPPARM-δ GW501516 has been abandoned because of safety issues, another SPPARM-δ (MBX-8025) and a dual PPAR-α/δ agonist (GFT-505) have shown promising efficacy in decreasing plasma triglyceride and increasing high-density lipoprotein cholesterol concentrations, as well as improving insulin sensitivity and liver function. The beneficial effects of GFT-505 are complemented by preclinical findings that indicate reduction of hepatic fat accumulation, inflammation and fibrosis, making it a promising candidate for the treatment of NAFLD/nonalcoholic steatohepatitis (NASH). Long-term trials are required to test the efficacy and safety of these new PPAR agonists in reducing cardiovascular outcomes and treating NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786 · cited 1×
“hepatic fatty acid b-oxidation and also attenuates hepatic inflammation, stellate cell proliferation and adipogenesis [27-29].”
BackgroundAthyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 13×
“Preclinical studies in rodent models of NAFLD/NASH (Western diet-fed human apo-E2 transgenic mice; methionine- and choline-deficient diet-fed db/db mice and CCl4-induced fibrotic rats) consistently demonstrated that GFT-505 treatment decreases hepatic steatosis, inflammation and fibrosis, decreases liver dysfunction b…”
BackgroundInfluentialStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 3×
“Preclinical studies in rodent models of NAFLD/NASH (Western diet-fed human apo-E2 transgenic mice; methionine- and choline-deficient diet-fed db/db mice and CCl4-induced fibrotic rats) consistently demonstrated that GFT-505 treatment decreases hepatic steatosis, inflammation and fibrosis, decreases liver dysfunction b…”
BackgroundSafety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 1×
“Although the PPAR-g agonists pioglitazone and rosiglitazone have been shown to exert beneficial effects on both metabolic (improvement in insulin sensitivity and glucose tolerance) and histological parameters (reduction of hepatic fat and inflammation) in patients with biopsy-proven NASH [30-36], clinical use of these…”
BackgroundLee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240 · cited 2×
“With respect to vascular risk, findings from large-scale Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials have shown that treatment with PPAR-a agonists (fibrates) reduces the risk of CV events in subgroups of diabetic subjects with a…”
BackgroundResultNagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233 · cited 1×
“Moreover, PPAR-a agonists downregulate the NF-kB pathway and reduce hepatic inflammation, and also upregulate the expression of both adiponectin and adiponectin receptors [24,25], which might be especially important for preventing progression of simple steatosis to NASH through enhancement of insulin sensitivity and r…”
BackgroundBruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Ghandehari, H., Kamal-Bahl, S., & Wong, N. D. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.005 · Cited by 180 · cited 1×
“It is the most common form of dyslipidemia in subjects with type 2 diabetes, metabolic syndrome and obesity, and is associated with an increased risk of atherosclerotic cardiovascular (CV) disease and coronary events beyond the effect of each individual component [2,3].”
BackgroundWatts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Self-citation
Cited by
Metabolic Flexibility in Health and Disease
Goodpaster, B. H., & Sparks, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.015 · Cited by 995
“Drugs that affect fatty acid oxidation, including PPAR agonists (Sahebkar et al., 2014), ACC inhibitors (Bourbeau and Bartberger, 2015), have been developed to affect fuel metabolism in obesity, diabetes and heart disease.”
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases
Ganjali, S., Gotto, A. M., Ruscica, M., Atkin, S. L., Butler, A. E., Banach, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27028 · Cited by 313
Self-citation
Metadata
- Authors
- Sahebkar, A., Chew, G. T., & Watts, G. F.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-01-16
- Volume
- 15
- Issue
- 4
- Pages
- 493-503
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2065886331
- Cited by
- 180
- References
- 15
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.